FTC and States Seek Contempt Order Against Martin Shkreli for Pharma Stock Trading
The Federal Trade Commission and seven states have petitioned a federal judge to hold Martin Shkreli in contempt for allegedly violating a 2022 lifetime ban on the pharmaceutical industry. The filing claims Shkreli traded in at least 60 pharma stocks and publicly commented on industry management since his release from prison. Regulators seek forced divestment of his holdings, fines based on trading profits, and potential incarceration for future breaches.